4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Special Call July 17, 2024 6:30 AM ET Company Participants Uneek Mehra - Chief Financial and Business Officer David Kirn - Chief Executive Officer and Co-Founder Robert Kim - Chief Medical Officer Arshad Khanani - Lead Investigator of PRISM Clinical Trial, Sierra Eye Associates Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - BofA Securities Jonathan Miller - Evercore ISI Gena Wang - Barclays Clara Dong - Jefferies Operator With that, ...

Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corrected visual acuity (BCVA) from baseline through Week 24 achieved at 3E10 vg/eye dose (+4.2 letters); dose response in favor of 3E10 vg/eye d ...

Investors are bullish on the stock due to the recent pipeline progress. Last month, the FDA cleared the company's investigational new drug application or 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with geographic atrophy. Earlier, the company presented positive data on its lead candidate, 4D-150, in wet age-related macular degeneration. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical resear ...

About 4D-175 for Geographic Atrophy Katherine Smith Inizio Evoke Comms Katherine.Smith@inizioevoke.com "GA is a leading cause of irreversible vision loss for over 5 million people globally and while current bolus complement inhibitor treatments reduce the rate of growth in GA lesions, they require burdensome monthly or bimonthly intravitreal injections and do not demonstrate functional vision benefit," said David Kirn, M.D., Cofounder and Chief Executive Officer of 4DMT. "4D-175 has the potential for durabl ...

EMERYVILLE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that the Company will present the initial interim 24-week landmark analysis from the Population Extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150 in a broad wet AMD patient population at the ASRS Annual Scientific ...

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24 Single intravitreal 3E10 vg/eye dose resulted in sustained reduction and stabilization of mean central subfield thickness (CST) compared to aflibercept at all timepoints EMERYVILLE, Calif., June 08, 2024 (GLOBE NEWSWIR ...

Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up Aerosolized 4D-710 was well tolerated at doses up to 1E15 vg (n=6) Dose-dependent and widespread 4D-710-mediated CFTR transgene RNA and protein expression observed in all lung biopsies from all participants evaluated to date Pre-existing AAV immunity cross-reactive with A101 did not affect transgene expression, biological ac ...

Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up Aerosolized 4D-710 was well tolerated at doses up to 1E15 vg (n=6) Dose-dependent and widespread 4D-710-mediated CFTR transgene RNA and protein expression observed in all lung biopsies from all participants evaluated to date Pre-existing AAV immunity cross-reactive with A101 did not affect transgene expression, biological ac ...

Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BST Company to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines ...

Exhibit 99.1 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights EMERYVILLE, Calif., May. 9, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported first quarter 2024 financial results and provided operational highlights. "The first quarter of 2024 kicks off another transformative year for 4DMT ...